Merck Remains Committed to RNAi Despite Shuttering Its California Facility

Merck confirmed that it is closing the San Francisco RNAi R&D facility it picked up through its acquisition of Sirna Therapeutics, but a spokesperson said that the company has not reduced its investment in the technology.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.